Promomed and the Almazov National Medical Research Centre signed a cooperation agreement at the IX St Petersburg Medical Innovation Forum. They will combine their efforts to develop healthcare in Russia’s Arctic regions.
According to the Centre, key health threats in the Arctic include high stress levels, shorter life expectancy, rising morbidity and disability among the working-age population. The Arctic zone’s lag behind national averages is documented in the country’s Arctic Development Strategy through 2035.
Academician Yevgeny Shlyakhto, director general of the Almazov Centre, said that metabolic health is one of the world’s biggest challenges, and solving it requires a synergy of science, education, digitalization and pharmaceutical innovation.
Alexander Yefremov, general director of Promomed, said the company is launching a large-scale study of Arctic residents’ health. “No major studies of the health of Arctic populations have been conducted for several decades,” he said. “We plan to study general and metabolic health in depth in order to develop pharmaceutical correction options to improve quality of life.” The study will have several stages and will continue until 2028.